{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:02:18Z","timestamp":1788321738364,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:00:00Z","timestamp":1489708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2017,7]]},"abstract":"\n Aims<\/jats:title>\n \n Glucagon\u2010like peptide\u20101 receptor agonists and dipeptidyl peptidase\u20104 inhibitors treat type 2 diabetes through incretin\u2010signaling pathways. This study compared the efficacy and safety of the glucagon\u2010like peptide\u20101 receptor agonist exenatide once\u2010weekly (\n M<\/jats:styled-content>\n iglyol) suspension for autoinjection (\n QWS\u2010AI<\/jats:styled-content>\n ) with the dipeptidyl peptidase\u20104 inhibitor sitagliptin or placebo.\n <\/jats:p>\n <\/jats:sec>\n \n Materials and methods<\/jats:title>\n \n In this open\u2010label, multicentre study of patients with type 2 diabetes who had suboptimal glycaemic control on metformin monotherapy, 365 patients were randomized to receive exenatide 2.0\u2009mg\n QWS\u2010AI<\/jats:styled-content>\n , sitagliptin 100\u2009mg once daily or oral placebo (3:2:1 ratio). The primary endpoint was change in glycated hemoglobin (\n HbA1c<\/jats:styled-content>\n ) from baseline to 28\u2009weeks.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n At 28\u2009weeks, exenatide\n QWS\u2010AI<\/jats:styled-content>\n significantly reduced\n HbA1c<\/jats:styled-content>\n from baseline compared to sitagliptin (\u22121.13% vs \u22120.75% [baseline values, 8.42% and 8.50%, respectively];\n \n P<\/jats:styled-content>\n <\/jats:italic>\n \u2009=\u2009.02) and placebo (\u22120.40% [baseline value, 8.50%];\n P<\/jats:italic>\n \u2009=\u2009.001). More exenatide\n QWS\u2010AI<\/jats:styled-content>\n \u2010treated patients achieved\n HbA1c<\/jats:styled-content>\n <7.0% than did sitagliptin\u2010 or placebo\u2010treated patients (43.1% vs 32.0% and 24.6%; both\n \n P<\/jats:styled-content>\n <\/jats:italic>\n \u2009<\u2009.05). Exenatide\n QWS\u2010AI<\/jats:styled-content>\n and sitagliptin reduced fasting plasma glucose from baseline to 28\u2009weeks (\u221221.3 and \u221211.3\u2009mg\/dL) vs placebo (+9.6\u2009mg\/dL), with no significant difference between the 2 active treatments. Body weight decreased with both active treatments (\u22121.12 and \u22121.19\u2009kg), but not with placebo (+0.15\u2009kg). No improvement in blood pressure was observed in any group. The most common adverse events with exenatide\n QWS\u2010AI<\/jats:styled-content>\n were gastrointestinal events and injection\u2010site reactions.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n This study demonstrated that exenatide\n QWS\u2010AI<\/jats:styled-content>\n reduced\n HbA1c<\/jats:styled-content>\n more than sitagliptin or placebo and was well tolerated.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12908","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T04:26:04Z","timestamp":1487219164000},"page":"979-988","source":"Crossref","is-referenced-by-count":53,"title":["Efficacy and safety of autoinjected exenatide once\u2010weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes:\n T<\/scp>\n he\n DURATION\u2010NEO<\/scp>\n \u20102 randomized clinical study"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1856-5574","authenticated-orcid":false,"given":"Kishore M.","family":"Gadde","sequence":"first","affiliation":[{"name":"Pennington Biomedical Research Center Louisiana State University Baton Rouge Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion L.","family":"Vetter","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayyar","family":"Iqbal","sequence":"additional","affiliation":[{"name":"AstraZeneca Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Hardy","sequence":"additional","affiliation":[{"name":"AstraZeneca Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"\u00d6hman","sequence":"additional","affiliation":[{"name":"AstraZeneca Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the DURATION\u2010NEO\u20102 study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0166-0"},{"key":"e_1_2_6_4_1","unstructured":"Byetta (exenatide) injection: US prescribing information. Wilmington DE: AstraZeneca Pharmaceuticals;2015."},{"key":"e_1_2_6_5_1","unstructured":"Bydureon (exenatide extended\u2010release) for injectable suspension: US prescribing information. Wilmington DE: AstraZeneca Pharmaceuticals;2015."},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2011.0050"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.28.4.157"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1932296815576186"},{"key":"e_1_2_6_9_1","first-page":"A283","article-title":"Pharmacokinetics and pharmacodynamics of a new exenatide formulation, exenatide suspension [abstract]","volume":"61","author":"MacConell L","year":"2012","journal-title":"Diabetes"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60590-9"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1107"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802418851"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0024"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-2905-1"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1374586"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2761"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60307-8"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.4137\/JCM.S16585"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12674"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60406-0"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61206-4"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-014-0171-2"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0172-0"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/11585880-000000000-00000"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02656.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12479"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01561.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30267-4"},{"key":"e_1_2_6_29_1","first-page":"S109","article-title":"DURATION\u2010NEO\u20101: greater HbA1c reductions with exenatide suspension once weekly by autoinjector pen vs exenatide twice daily in inadequately controlled type 2 diabetes","volume":"57","author":"Wysham C","year":"2014","journal-title":"Diabetologia"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12908","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:45:59Z","timestamp":1761860759000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,17]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1111\/dom.12908"],"URL":"https:\/\/doi.org\/10.1111\/dom.12908","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,17]]}}}